164 related articles for article (PubMed ID: 24850175)
1. Potent antitumor activity of HSP90 inhibitor AUY922 in adrenocortical carcinoma.
Huang J; Sun C; Zhang T; Pan L; Wang S; He Q; Li D
Tumour Biol; 2014 Aug; 35(8):8193-9. PubMed ID: 24850175
[TBL] [Abstract][Full Text] [Related]
2. Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy.
Cheng W; Ainiwaer A; Xiao L; Cao Q; Wu G; Yang Y; Mao R; Bao Y
Mol Med Rep; 2015 Aug; 12(2):2451-6. PubMed ID: 25955495
[TBL] [Abstract][Full Text] [Related]
3. A novel heat shock protein 90 inhibitor potently targets adrenocortical carcinoma tumor suppression.
Wang T; Subramanian C; Blagg BSJ; Cohen MS
Surgery; 2020 Jan; 167(1):233-240. PubMed ID: 31561992
[TBL] [Abstract][Full Text] [Related]
4. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
[TBL] [Abstract][Full Text] [Related]
5. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
6. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
Bao XH; Takaoka M; Hao HF; Fukazawa T; Yamatsuji T; Sakurama K; Takigawa N; Nakajima M; Fujiwara T; Naomoto Y
Oncol Rep; 2013 Jan; 29(1):45-50. PubMed ID: 23064324
[TBL] [Abstract][Full Text] [Related]
8. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.
Taniguchi H; Hasegawa H; Sasaki D; Ando K; Sawayama Y; Imanishi D; Taguchi J; Imaizumi Y; Hata T; Tsukasaki K; Uno N; Morinaga Y; Yanagihara K; Miyazaki Y
Cancer Sci; 2014 Dec; 105(12):1601-8. PubMed ID: 25263741
[TBL] [Abstract][Full Text] [Related]
9. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.
Zaidi S; McLaughlin M; Bhide SA; Eccles SA; Workman P; Nutting CM; Huddart RA; Harrington KJ
PLoS One; 2012; 7(4):e35436. PubMed ID: 22523597
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of heat shock protein 90 with AUY922 represses tumor growth in a transgenic mouse model of islet cell neoplasms.
Fendrich V; Wichmann S; Wiese D; Waldmann J; Lauth M; Rexin P; L-Lopez C; Schlitt HJ; Bartsch DK; Lang SA
Neuroendocrinology; 2014; 100(4):300-9. PubMed ID: 25301256
[TBL] [Abstract][Full Text] [Related]
11. Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer.
Yeramian A; García V; Bergadà L; Domingo M; Santacana M; Valls J; Martinez-Alonso M; Carceller JA; Cussac AL; Dolcet X; Matias-Guiu X
Mol Imaging Biol; 2016 Aug; 18(4):545-56. PubMed ID: 26604096
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.
Wang CY; Guo ST; Wang JY; Liu F; Zhang YY; Yari H; Yan XG; Jin L; Zhang XD; Jiang CC
Mol Cancer Ther; 2016 Mar; 15(3):448-59. PubMed ID: 26832792
[TBL] [Abstract][Full Text] [Related]
13. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
14. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
[TBL] [Abstract][Full Text] [Related]
15. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ
Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.
Wainberg ZA; Anghel A; Rogers AM; Desai AJ; Kalous O; Conklin D; Ayala R; O'Brien NA; Quadt C; Akimov M; Slamon DJ; Finn RS
Mol Cancer Ther; 2013 Apr; 12(4):509-19. PubMed ID: 23395886
[TBL] [Abstract][Full Text] [Related]
17. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
Augello G; Emma MR; Cusimano A; Azzolina A; Mongiovì S; Puleio R; Cassata G; Gulino A; Belmonte B; Gramignoli R; Strom SC; McCubrey JA; Montalto G; Cervello M
Int J Cancer; 2019 May; 144(10):2613-2624. PubMed ID: 30488605
[TBL] [Abstract][Full Text] [Related]
18. HSP90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells.
Liu J; Sun W; Dong W; Wang Z; Qin Y; Zhang T; Zhang H
Biochem Biophys Res Commun; 2017 May; 487(2):313-319. PubMed ID: 28412368
[TBL] [Abstract][Full Text] [Related]
19. Chloroquine enhances the efficacy of cisplatin by suppressing autophagy in human adrenocortical carcinoma treatment.
Qin L; Xu T; Xia L; Wang X; Zhang X; Zhang X; Zhu Z; Zhong S; Wang C; Shen Z
Drug Des Devel Ther; 2016; 10():1035-45. PubMed ID: 27022243
[TBL] [Abstract][Full Text] [Related]
20. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]